By Counterforce Health Team in Humira (adalimumab) —

How to Get Humira (adalimumab) Covered by Humana in North Carolina: Complete 2025 Guide with Forms and Appeals

Answer Box: Getting Humira Covered by Humana in North Carolina

Humana Medicare Advantage and Part D plans require prior authorization for Humira (adalimumab) with step therapy mandating biosimilar trials first. In North Carolina, you have 65 days to appeal denials internally with Humana, then 120 days for external review through Smart NC. Quick steps: 1) Gather biosimilar failure documentation and medical records, 2) Submit PA via Humana provider portal or call 800-457-4708, 3) If denied, request peer-to-peer review, then file appeals within deadlines.

Table of Contents

  1. Humana's Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Step Therapy & Biosimilar Requirements
  4. Quantity Limits and Frequency Rules
  5. Required Diagnostics and Lab Work
  6. Specialty Pharmacy Network
  7. Evidence to Support Medical Necessity
  8. Appeals Process in North Carolina
  9. Common Denial Reasons & Solutions
  10. Cost-Saving Options
  11. FAQ

Humana's Coverage Policy Overview

Humana covers Humira (adalimumab) across its Medicare Advantage and Part D plans, but with significant restrictions that have tightened in 2025. The medication typically sits on Tier 4 or 5 (specialty tier) with high cost-sharing, and prior authorization is required for all new starts.

Plan Types and Coverage

  • Medicare Advantage (Part C): Covers Humira as part of medical benefits for certain indications
  • Medicare Part D: Covers as specialty pharmacy drug with formulary restrictions
  • Coverage varies by ZIP code - use Humana's drug list search tool to verify your specific plan's coverage
Note: Humana processed 2.2 prior authorization requests per enrollee in 2024, with a 5.8% denial rate—below the industry average but still requiring careful documentation.

Medical Necessity Requirements

FDA-Approved Indications

Humana covers Humira for these FDA-approved conditions:

  • Rheumatoid arthritis (moderate to severe)
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Plaque psoriasis (moderate to severe)
  • Hidradenitis suppurativa (moderate to severe)
  • Crohn's disease (moderate to severe)
  • Ulcerative colitis (moderate to severe)
  • Non-infectious uveitis
  • Juvenile idiopathic arthritis (ages 4+)

Documentation Requirements

Your prescriber must document:

  • Confirmed diagnosis with appropriate ICD-10 codes
  • Disease severity assessment using validated scales (DAS28 for RA, Mayo Score for IBD)
  • Treatment goals and expected outcomes
  • Contraindications to conventional therapy
  • Infection screening results (TB, hepatitis B)

Step Therapy & Biosimilar Requirements

Humana requires documented failure of preferred adalimumab biosimilars before approving brand-name Humira. This is the most common reason for initial denials in 2025.

Required Biosimilar Trials

You must try these first (unless contraindicated):

  • Amjevita (adalimumab-atto)
  • Cyltezo (adalimumab-adbm)
  • Other preferred biosimilars per your plan's formulary

Documenting Biosimilar Failure

For each failed biosimilar, provide:

  • Dates of therapy (start and stop)
  • Doses and frequency administered
  • Duration of adequate trial (typically 12+ weeks)
  • Specific reason for failure:
    • Inadequate response (with disease activity scores)
    • Intolerable side effects (documented in medical records)
    • Contraindication (medical reason why biosimilar couldn't be used)

Medical Exceptions to Step Therapy

You can bypass biosimilar requirements if you have:

  • Previous documented failure of the required biosimilars
  • Medical contraindication to biosimilar ingredients
  • Urgent clinical situation requiring immediate brand-name therapy

Quantity Limits and Frequency Rules

Standard Quantity Limits

Indication Typical Limit Frequency
RA, PsA, AS 2-4 pens per 28 days Every other week
Plaque Psoriasis 2-4 pens per 28 days Every other week
IBD (Crohn's, UC) 2-4 pens per 28 days Every other week
Hidradenitis Suppurativa 2-4 pens per 28 days Weekly initially, then every other week

Requesting Quantity Limit Exceptions

For higher doses, your prescriber must document:

  • Clinical rationale for increased frequency
  • Weight-based dosing calculations if applicable
  • Previous response to standard dosing
  • Safety monitoring plan

Required Diagnostics and Lab Work

Mandatory Screening Tests

Before Humira approval, Humana requires:

Infection Screening:

  • Tuberculosis testing: QuantiFERON-Gold or tuberculin skin test
  • Hepatitis B panel: HBsAg, anti-HBc, anti-HBs
  • Hepatitis C screening if risk factors present
  • Complete blood count with differential

Disease Activity Assessment:

  • Rheumatoid arthritis: DAS28, CDAI, or SDAI scores
  • IBD: Mayo Score (UC) or CDAI (Crohn's)
  • Psoriasis: PASI or BSA involvement

Timing Requirements

  • Tests must be within 3 months of PA submission
  • Active infections must be treated before approval
  • Latent TB treatment must be started before Humira initiation

Specialty Pharmacy Network

Humana requires Humira to be dispensed through network specialty pharmacies for optimal coverage.

Preferred Specialty Pharmacies

  • CenterWell Specialty Pharmacy: 1-800-486-2668 (Humana's preferred option)
  • Accredo: 1-800-922-8279
  • CVS Specialty: 1-800-552-8159
  • Optum Specialty: 1-855-427-4682

Benefits of Using CenterWell

  • Lower cost-sharing compared to other network pharmacies
  • 24/7 pharmacist support for injection training
  • Financial assistance program coordination
  • Home delivery with temperature-controlled shipping
  • Adherence monitoring and refill reminders
Tip: Use Humana's Pharmacy Finder to verify network status and Humira availability at your preferred specialty pharmacy.

Evidence to Support Medical Necessity

Clinical Guidelines to Reference

When appealing denials, reference these authoritative sources:

  • FDA prescribing information for Humira
  • American College of Rheumatology guidelines for RA/PsA treatment
  • American Gastroenterological Association guidelines for IBD
  • American Academy of Dermatology guidelines for psoriasis

Documentation Best Practices

Medical Necessity Letter Should Include:

  1. Patient's clinical history and diagnosis
  2. Previous therapies tried with specific dates and outcomes
  3. Contraindications to preferred alternatives
  4. Clinical rationale for Humira specifically
  5. Treatment goals and monitoring plan
  6. Relevant guideline citations

Appeals Process in North Carolina

Humana Internal Appeals

Timeline: 65 days from denial notice to file appeal

Standard Process:

  1. File online at resolutions.humana.com
  2. Call expedited line: 866-274-5888 (for urgent situations)
  3. Mail appeals to address on denial notice
  4. Include: Policy number, denial details, supporting medical records

Decision Timeframes:

  • Part D appeals: 7 calendar days
  • Part C pre-service: 30 calendar days
  • Expedited appeals: 48 hours or sooner

North Carolina External Review

If Humana denies your internal appeal, North Carolina residents can request external review through Smart NC.

Key Details:

  • Filing deadline: 120 days from Humana's appeal decision
  • Contact: NC Department of Insurance at 855-408-1212
  • Online portal: smart.ncdoi.gov (verify current URL)
  • Decision timeline: 45 days standard, 72 hours expedited

Smart NC Process:

  1. Submit external review request with denial letters and medical records
  2. Independent Review Organization assigned by Smart NC
  3. Binding decision on Humana if overturned
  4. Free advocacy support available through Smart NC helpline
Important: North Carolina's external review applies to Medicare Advantage plans but may not cover pure Part D denials, which follow federal IRE (Independent Review Entity) processes.

Common Denial Reasons & Solutions

Denial Reason Required Documentation Action Steps
Step therapy not met Biosimilar trial records with dates, doses, failure reasons Gather pharmacy records, provider notes documenting inadequate response or intolerance
Insufficient medical necessity Disease activity scores, treatment history, clinical rationale Request peer-to-peer review with Humana medical director
Missing infection screening TB testing, hepatitis panel results Complete required labs within 3 months of resubmission
Non-formulary status Formulary exception request with clinical justification Submit exception request with comparative effectiveness evidence
Quantity limit exceeded Dosing rationale, weight-based calculations Provide clinical evidence for higher dose requirements

Peer-to-Peer Review Strategy

Request within 24-48 hours of denial by calling Humana provider services. Success rate is 80-85% when proper documentation is provided.

Preparation for peer-to-peer:

  • Have patient's complete medical history available
  • Prepare biosimilar failure timeline
  • Reference specific clinical guidelines
  • Emphasize urgency if applicable

Cost-Saving Options

2025 Medicare Part D Changes

  • Out-of-pocket maximum: $2,100 total annual cap
  • Deductible: Up to $601 (varies by plan)
  • Coverage gap eliminated: No more "donut hole"

Financial Assistance Programs

Humira Complete Support Program:

  • Copay cards for eligible commercially insured patients
  • Patient assistance program for uninsured/underinsured
  • Nurse ambassador support for injection training
  • Contact: 1-800-4HUMIRA (1-800-448-6472)

Medicare-Specific Options:

  • Extra Help (Low-Income Subsidy): Reduces copays to ~$4.50 for specialty drugs
  • State Pharmaceutical Assistance Programs: Check North Carolina eligibility
  • Manufacturer patient assistance: For those who don't qualify for other programs
From our advocates: "We've seen patients save thousands by combining Medicare Extra Help with manufacturer assistance programs. The key is applying for all available programs simultaneously, as eligibility requirements often complement each other."

Counterforce Health helps patients navigate these complex coverage requirements by turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters alongside plan policies and clinical notes to identify the specific coverage gaps and draft point-by-point rebuttals that align with Humana's own approval criteria.

FAQ

How long does Humana prior authorization take for Humira in North Carolina? Standard PA decisions take 72 hours for Part D, up to 30 days for Part C. Expedited reviews (when delay could harm health) are decided within 24-72 hours.

What if Humira is not on my Humana formulary? You can request a formulary exception by having your prescriber submit clinical documentation showing medical necessity and why preferred alternatives are inappropriate.

Can I get expedited approval for Humira? Yes, if your prescriber documents that a delay would seriously jeopardize your health or ability to regain function. Submit urgency documentation with your PA request.

Do I need to retry biosimilars if I failed them outside North Carolina? No, documented failure of required biosimilars from any location should satisfy step therapy requirements. Ensure your new prescriber has access to those medical records.

What happens if Smart NC overturns Humana's denial? Humana must provide coverage within 3 business days of the external review decision. The IRO's decision is binding on the insurance company.

How much will Humira cost with Humana coverage? Costs vary by plan tier and coverage phase. Specialty tier drugs typically have 25-50% coinsurance until you reach the $2,100 out-of-pocket maximum, after which Medicare pays 100%.

For complex denials involving multiple coverage issues, Counterforce Health provides specialized support in crafting appeals that address each specific denial reason with the clinical evidence and policy citations that payers require for approval.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeals processes may change. Always verify current requirements with Humana and consult your healthcare provider for medical decisions. For personalized assistance with insurance appeals, contact North Carolina's Smart NC program at 855-408-1212.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.